Tandem Therapeutics’ Post

Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company, has secured a new $10 million debt facility. This financing enables the company to pay off a higher interest rate loan and fund operations to generate additional data supporting the new drug application for its lead candidate, CNM-Au8(R), for treating amyotrophic lateral sclerosis (ALS). 'We believe that the proceeds from this new debt facility, including an extended interest-only period, will allow Clene the cash runway to generate the additional data the U.S. Food and Drug Administration has requested from our expanded access programs,' said Clene CEO and President Rob Etherington. 'The data are being gathered to support the existing clinical study data for inclusion in an application seeking approval of CNM-Au8 for ALS through the accelerated regulatory pathway.' Clene and its subsidiary, Clene Nanomedicine Inc., focus on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases like ALS and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that targets mitochondrial function and the NAD pathway while reducing oxidative stress. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. #ALS #Neurodegenerative #Biotech

🚀 Are you attending #TIDES2024 in Hamburg, Germany, November 11-14? Let’s connect at booth #316! Our experts, Cátia Teixeira and Luísa Aguiar, are excited to share how our PurePep solutions can elevate your peptide projects to the next level. 💡 The peptide therapeutics landscape is rapidly evolving, driven by two major trends: ⭐ Innovative Screening Platforms: Chemical and display screening platforms are becoming the new standard for target-based drug development, enriching the preclinical pipeline significantly. ⭐ GLP-1 Analogs Success: The breakthrough in GLP-1 analogs for weight loss and obesity is transforming pharmaceutical interest in peptides, leading to high demand and a capacity crunch in synthesis. We’re here to help you navigate these changes—see you in Hamburg! #purepep #forpeptidescientists #synthesis #purification

The pharmaceutical industry in 2024 is undergoing a major shift, fueled by advances in biotechnology, precision medicine, and changing market demands. With a strong focus on oncology, neurological diseases, and biologics, R&D efforts are hitting new heights. This year’s pipeline reveals some key trends—dominated by innovative drug types and new players stepping up in the global R&D race.

Clene Nanomedicine, Inc.. has made significant strides in its neurodegenerative disease research during the third quarter of 2024, particularly in amyotrophic lateral sclerosis (ALS) treatment development. The biopharmaceutical company recently engaged in a critical FDA meeting to explore potential accelerated approval pathways for its investigational therapy CNM-Au8. This breakthrough candidate targets mitochondrial health and neuronal function, representing a novel approach in ALS treatment. Financially, Clene concluded the quarter with $14.6 million in cash reserves and reported a net loss of $8.0 million. The company strategically reduced research and development expenses while maintaining focus on its core clinical objectives. A notable corporate action included a 1-for-20 reverse stock split to ensure compliance with Nasdaq listing requirements. Additionally, Clene secured an amended debt facility extending funding capabilities into the second quarter of 2025. The company's Phase 3 RESTORE-ALS trial, presented in October, underscores Clene's commitment to innovative neurological disease research. By targeting mitochondrial function and the NAD pathway, CNM-Au8 represents a promising therapeutic approach for patients battling progressive neurological conditions. Clene continues to position itself as a leader in developing potential breakthrough treatments for neurodegenerative diseases, with a strategic focus on improving cellular survival and reducing oxidative stress. #Biotech #MedicalInnovation #NeurologicalResearch

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, recently participated in two investor conferences to present updates on its lead drug candidate, CNM-Au8®. The company gave a fireside presentation at the 2024 Maxim Healthcare Virtual Summit on October 15 and will present at The ThinkEquity Conference 2024 on October 30 in New York. CNM-Au8® has shown promising results in restoring and protecting neurological function, offering hope for patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS and is scheduled to meet with the FDA leadership in November. The company's focus on improving mitochondrial health and protecting neuronal function has garnered interest from investors, as CNM-Au8® targets a crucial aspect of neurodegenerative diseases. @clene_inc's participation in these conferences highlights its commitment to keeping investors informed about its progress and achievements. #biotechnology #neurodegenerative #investorconferences #clnn @clene_inc

🌟GRADUATION PROJECT🌟 Have you ever heard of Nanomedicine? Do you think it's going to bring a revolution to healthcare? I started working on my graduation project last month and I decided to do my project with the department of Pharmaceutical Technology. After speaking with my supervisor, we decided to work on Nanoparticles placebo and analyse them based on particle size, zeta potential and addition order of the polymers. What is Nanoparticle drug delivery system? Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. This modern form of a drug delivery system would help minimize side-effects and reduce drug dosage(amount of drugs taken by the patient). Based on the effectiveness of this drug delivery system, it can really help with cancer patients and ensure that the chemotherapeutic drugs are encapsulated in nanoparticles to only target cancer cells and not destroy healthy cells. In this video, I explained Nanoparticles drug delivery system in simple terms. Your Legal Drug Dealer #Pharmacystudent #finals #Gradproject #Thesis #Nanomedicine #Nanoparticle #Nanotechnology #Healthcare #PharmaceuticalTechnology #Drugs

Exciting times ahead for the pharmaceutical industry! Innovation in biotech, precision medicine, and a strong focus on oncology and neurology are shaping the future of healthcare. The race in global R&D is heating up with groundbreaking drug developments. Looking forward to what 2025 brings!

Established leaders like Roche and Pfizer maintain their dominance with extensive pipelines, but the presence of companies like Hengrui and Fosun Pharma highlights the growing influence of players from emerging markets. Are we witnessing a reshape of the pharmaceutical landscape, where traditional giants face increasing competition from newer entrants? 

Today on World Lung Day let's raise awareness about lung health and promote better lung care worldwide. Increasing research on lung disorders is likely to create growth opportunities for the In Vitro Lung Model Market within the North America. Moreover, the presence of a significant number of pharmaceutical and biotechnology companies, as well as academic research institutions further drives the market in Asia Pacific region. To gather more such facts from the In Vitro Lung Model Market, click @ https://lnkd.in/gE2SjF9T #GVR #marketresearch #researchinsights #LungHealth #InVitroLungModel #LungHealth #research #LungHealthDay #WorldLungHealthDay

Discovery US 2024 By Oxford Global As recent technological and pharmacological advances tackle the previously ‘undruggable’, Discovery US returns to support the discovery of novel pharmaceutical modalities beyond the rule of five – including novel degraders, molecular glues, orally-available peptides and radioligands. Oxford Global's jam packed two-day agenda showcases the key platforms and technologies impacting early drug pipelines, from DNA-encoded libraries and phenotypic screening through to AI algorithms and organoid models. It brings together experts in target discovery and validation from across small & large biopharma organizations to discuss how the newest therapeutic paradigms can overcome historic challenges in drug development and provide optimized, novel drug candidates. Join the all star line up including: Abhijat Vatsyayan, Divya Kanichar, Fiona Mack, Giovanni Piedimonte, Graham T. Dempsey, Hong Cheng, Jason Ekert, Jennifer Caldwell Busby, Julie Owen, Martin Redhead, Paul Scola, Shelley Allen, for whats set to be a ground-breaking event!